Senesco is running a Phase 1/2 study in multiple myeloma, diffuse large B-cell lymphoma and mantle cell lymphoma patients with a novel gene regulatory approach. The ability of eukaryotic translation initiation factor 5A (eIF5A) to modulate critical pathways involved in cancer and inflammatory diseases is being investigated.